文献速递消化道肿瘤放疗姑息放疗与转移瘤

立体定向消融放疗治疗寡转移性胰腺导管腺癌以延缓多部位进展、减少化疗并改善结局

Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-24

本回顾性研究纳入20例接受立体定向消融放疗(SABR)的寡转移性胰腺导管腺癌(OPanc)患者与21例未接受SABR的相似患者,SABR组中位多部位进展无生存期40个月 vs 化疗组14个月(HR=0.2,95%CI 0.07-0.54,P=.0009),中位总生存期42个月 vs 18个月(HR=0.21,95%CI 0.08-0.53,P=.0003),作者认为SABR可改善选定人群的结局并需前瞻性评估。

要点

  • SABR组85%(17/20)患者化疗间歇≥6个月,化疗组为33.3%(7/21)。
  • SABR组中位多部位进展无生存期40个月 vs 化疗组14个月(HR=0.2)。
  • SABR组中位总生存期42个月 vs 化疗组18个月(HR=0.21)。

核心结论

  • 以SABR作为局部区域治疗管理OPanc可能改善选定人群的结局,并需前瞻性评估。

研究设计与样本

  • 回顾性研究,纳入同步或异时性OPanc(1至5个转移灶)接受SABR至所有活动转移灶的患者20例。
  • 设立 comparable 组:转移负荷相似、CA19-9范围相近且至少5个月无进展但未接受SABR的患者21例。
  • 另设IV期胰腺导管腺癌且超过5个远处病灶(多转移)的第三组,以帮助定义多部位进展后的预期结局。

主要发现

  • SABR组20例中17例(85%)化疗间歇≥6个月,化疗组21例中7例(33.3%)化疗间歇≥6个月。
  • SABR组与化疗组中位多部位进展无生存期分别为40个月和14个月(HR=0.2;95%CI 0.07-0.54;P=.0009)。
  • SABR组与化疗组中位总生存期分别为42个月和18个月(HR=0.21;95%CI 0.08-0.53;P=.0003)。
  • SABR共照射38个转移瘤。

临床怎么用

  • 作者认为,以SABR作为局部区域治疗管理OPanc可能改善选定人群的结局,并需前瞻性评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The oligometastatic state is observed in patients across many malignancies, with increased recognition regarding improved outcomes after local therapies. However, there is limited data specifically regarding pancreatic ductal adenocarcinoma. We hypothesized that an oligometastatic pancreatic ductal adenocarcinoma (OPanc) phenotype would benefit from stereotactic ablative radiation therapy (SABR) to all active metastatic sites. Here, we report our institutional experience of SABR-treated OPanc to evaluate the feasibility of the approach. METHODS AND MATERIALS: A retrospective review of patients with synchronous or metachronous OPanc (1 to 5 metastases) who received SABR to all active metastatic sites was performed. We identified a comparable group of patients with similar metastatic burden, range of CA19-9 levels, and no progression for at least 5 months who did not receive SABR. We compared overall survival as the primary outcome, and polyprogression-free survival and time off chemotherapy as the secondary exploratory assessments. A third group presenting with stage IV pancreatic ductal adenocarcinoma and more than 5 distant lesions (polymetastatic) was identified to help define expected outcomes after polyprogression. RESULTS: Our study included 20 patients with OPanc receiving SABR and 21 who did not. SABR was delivered to 38 metastatic tumors. Out of the 20 SABR-treated OPanc patients, 17 (85%) had 6 or more months of time off chemotherapy, compared with 7 patients (33.3%) among the chemotherapy-treated group. Median polyprogression-free survival was 40 and 14 months (hazard ratio = 0.2; 95% confidence interval, 0.07-0.54; P = .0009), and overall survival was 42 and 18 months (hazard ratio = 0.21; 95% confidence interval, 0.08-0.53; P = .0003), for SABR- and chemotherapy-treated cohorts, respectively. CONCLUSIONS: Management of OPanc with SABR as local regional therapy could improve outcomes in a selected population and warrants prospective evaluation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Elamir AM, Karalis JD, Sanford NN, et al. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Int J Radiat Oncol Biol Phys. 2022. PMID: 35896145. doi:10.1016/j.ijrobp.2022.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。